Faculty of Medicine, Department of Pediatric Oncology, Gazi University, Ankara, Turkey.
Pediatr Blood Cancer. 2010 Dec 15;55(7):1272-7. doi: 10.1002/pbc.22722. Epub 2010 Aug 23.
A number of clinical studies conducted in adults have demonstrated the prognostic significance of angiogenic factors in malignancies, however, only a limited number of studies have been conducted in children. The aim of this study was to determine serum vascular endothelial growth factor (VEGF), endostatin, and leptin levels in children with lymphoma and to investigate whether these factors provide prognostic information.
Serum samples from 36 children with lymphoma (non-Hodgkin lymphoma (NHL) N = 21, Hodgkin lymphoma (HL) N = 15) were collected at diagnosis and during remission. Serum samples were also collected from 18 healthy children as the control group. Serum VEGF and endostatin levels were quantified by using enzyme-linked immunosorbent assay (ELISA) and serum leptin by immunoradiometric assay.
The serum VEGF levels were found elevated in patients compared to controls (P = 0.033), while endostatin and leptin levels were lower in patients than in controls (endostatin, 43.9 ± 5.8 ng/ml vs. 123.6 ± 13.5 ng/ml, P < 0.001; leptin, 5 ± 1.5 ng/ml vs. 6.7 ± 1.2 ng/ml, P = 0.013). VEGF levels declined (pre, 151.6 ± 55.9 pg/ml vs. post, 16.2 ± 7.9 pg/ml, P = 0.041), while endostatin and leptin levels increased in patients who achieved remission (33 of 36 patients) when compared to pre-treatment levels (endostatin pre, 43.1 ± 5.9 ng/ml vs. post, 65.9 ± 6.8 ng/ml, P = 0.047; leptin, pre, 5.3 ± 1.6 ng/ml vs. post, 9.8 ± 2.7 ng/ml, P = 0.012). Serum VEGF, endostatin, and leptin levels were not predictive of survival.
Serial measurement of serum VEGF, endostatin, and leptin levels could potentially be used to predict response to treatment or progressive disease in children with lymphoma.
多项针对成年人的临床研究表明，血管生成因子在恶性肿瘤中具有预后意义，但在儿童中仅有少数研究进行。本研究旨在确定淋巴瘤患儿血清血管内皮生长因子（VEGF）、内皮抑素和瘦素水平，并探讨这些因素是否提供预后信息。
在诊断和缓解期采集 36 例淋巴瘤患儿（非霍奇金淋巴瘤（NHL）N=21，霍奇金淋巴瘤（HL）N=15）的血清样本。另采集 18 例健康儿童的血清样本作为对照组。采用酶联免疫吸附试验（ELISA）测定血清 VEGF 水平，免疫放射分析法测定血清内皮抑素和瘦素水平。
与对照组相比，患儿血清 VEGF 水平升高（P=0.033），而内皮抑素和瘦素水平降低（内皮抑素，43.9±5.8ng/ml 比 123.6±13.5ng/ml，P<0.001；瘦素，5±1.5ng/ml 比 6.7±1.2ng/ml，P=0.013）。缓解的 36 例患儿中，33 例 VEGF 水平下降（治疗前，151.6±55.9pg/ml 比治疗后，16.2±7.9pg/ml，P=0.041），而内皮抑素和瘦素水平升高（治疗前，43.1±5.9ng/ml 比治疗后，65.9±6.8ng/ml，P=0.047；瘦素，治疗前，5.3±1.6ng/ml 比治疗后，9.8±2.7ng/ml，P=0.012）。血清 VEGF、内皮抑素和瘦素水平均不能预测生存。
血清 VEGF、内皮抑素和瘦素水平的连续测量可能有助于预测儿童淋巴瘤对治疗的反应或疾病进展。
